A better cell cycle target for gene therapy of colorectal cancer: Cyclin G

Journal of Gastrointestinal Surgery

Volumn 7, Issue 7, 2003, Pages 884-889

  Perez, Rodrigo ^a   Wu, Nancy ^b   Klipfel, Adam A ^b   Beart Jr , Robert W ^b   Charles, W ^b   Costello, C ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer epidemiology; Colon cancer

Indexed keywords

CYCLIN D1; CYCLIN G; CYCLINE; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CELL CYCLE; CLINICAL FEATURE; COLON; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; GENE THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; RECTUM; RECTUM CANCER; SEX RATIO; TUMOR DIFFERENTIATION;

EID: 0242365568     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gassur.2003.08.001     Document Type: Article

References (20)

1. Vogelstein B., Kinzler K.W. The multistep nature of cancer. Trends Genet. 9:1993;138-141.
2. Gillett C.E., Barnes D.M. Demystified: Cell cycle. Br Med J. 51:1998;310-316.
3. Bartek J., Lukas J. Order from destruction. Science. 294:2001;66-67.
4. Roberts J.M. Evolving ideas about cyclins. Cell. 98:1999;129-132.
5. Arber N., Hibshoosh H., Moss S.F., et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology. 110:1996;669-674.
6. Utsonomyia T., Doki Y., Takemoto H., et al. Correlation of beta-catenin and cyclin D1 expression in colon cancers. Oncology. 61:2001;226-233.
7. Jung A., Schrauder M., Oswald U., et al. The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1 and p16 and is a region of low proliferation. Am J Pathol. 159:2001;1613-1617.
8. Reimer C.L., Borras A.M., Kurdistani S.K., et al. Altered regulation of cyclin G in human breast cancer and its specific localization at replication foci in response to DNA damage in p53+/+ cells. J Biol Chem. 274:1999;11022-11029.
9. Pines J., Hunter T. Cyclins and cancer II: Cyclin D1 and CDK inhibitors come of age. Cell. 79:1994;573-582.
10. Jiang W., Kahn S.M., Zhou P., et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene. 8:1993;3447-3457.
11. Lovec H., Sewing A., Lucibello F.C., et al. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: Link between cell cycle control and malignant transformation. Oncogene. 9:1994;709-713.
12. Sherr C.J. The Pezcoller lecture: Cancer cell cycles revisited. Cancer Res. 60:2000;3689-3695.
13. Weinstein I.B. Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. J Cell Biochem Suppl. 252:1996;23-28.
14. Ikeguchi M., Sakatani T., Ueta T., Kaibara N. Cyclin D1 expression and retinoblastoma protein expression in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 127:2001;531-536.
15. Bartkova J., Lukas J., Muller H. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer. 58:1994;353-361.
16. Skotzo M., Wu L., Anderson W.F. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res. 55:1995;5493-5498.
17. Smith M.L., Bortnick R., Sheikh M.S., Fornace A.L. Jr. Chromatin relaxation by overexpression of mutant p53, HPV16-E6, or cyclin G transgenes. Exp Cell Res. 242:1998;235-243.
18. Chen D.S., Zhu N.L., Hung G., et al. Retroviral vector-mediated transfer of an antisense cyclin G1 construct inhibits osteosarcoma tumor growth in nude mice. Hum Gene Ther. 14:1997;1667-1674.
19. Okamoto K., Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 13:1994;4816-4822.
20. Zauberman A., Lupo A., Oren M. Identification of p53 target genes through immune selection of genomic DNA: The cyclin G gene contains two distinct p53 binding sites. Oncogene. 10:1995;2361-2366.